Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation.
UMass Chan AffiliationsDepartment of Biochemistry and Molecular Pharmacology
Document TypeJournal Article
In Vitro Techniques
Small Molecule Libraries
Enzymes and Coenzymes
MetadataShow full item record
AbstractPAD4 has been strongly implicated in the pathogenesis of autoimmune, cardiovascular and oncological diseases through clinical genetics and gene disruption in mice. New selective PAD4 inhibitors binding a calcium-deficient form of the PAD4 enzyme have validated the critical enzymatic role of human and mouse PAD4 in both histone citrullination and neutrophil extracellular trap formation for, to our knowledge, the first time. The therapeutic potential of PAD4 inhibitors can now be explored.
SourceNat Chem Biol. 2015 Mar;11(3):189-91. doi: 10.1038/nchembio.1735. Link to article on publisher's site
Permanent Link to this Itemhttp://hdl.handle.net/20.500.14038/50030
Full author list omitted for brevity. For the full list of authors, see article.
Related ResourcesLink to Article in PubMed